AbbVie Biotech Ventures
VC Fund
North Chicago, United States
AbbVie Biotech Ventures is a VC fund in North Chicago focused on Biotechnology and Health Care. AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Togetherwith its wholly-owned subsidiary, Pharmacyclics, AbbVie employs ~29,000 people worldwide and markets medicines in more than 175 countries.
- Total investments:
- 49
- Last investment:
- Lead investor:
- 16%
Last updated:
For AI agents: llms.txt
Industries AbbVie Biotech Ventures invests in
Stages AbbVie Biotech Ventures invests in
Countries AbbVie Biotech Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $6M–$53M
- Series B
- $12M–$83M
- Series C
- $39M–$115M
Investment Focus
Industry
- Biotechnology 34 (69%)
- Health Care 19 (39%)
- Therapeutics 18 (37%)
- Pharmaceutical 12 (24%)
- Medical 9 (18%)
Stage
- Series A 19 (39%)
- Series B 11 (22%)
- Series C 5 (10%)
- Seed 4 (8%)
- Series D 2 (4%)
Country
- United States 29 (59%)
- China 1 (2%)
- Italy 1 (2%)
- Germany 1 (2%)
- Australia 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Jay Cui
Manager
|
Manager | Total investments: 0 | Find email | |
John Gustofson
Managing Director
|
Managing Director | Total investments: 11 | Find email | |
Scott Brun
Head
|
Head | Total investments: 1 | Find email | |
Margarita Chavez
Managing Director
|
Managing Director | Total investments: 15 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| DISCO Pharmaceuticals is a firm that specializes in large-scale surfaceome unlocking of cancer cells. | $21.8M / Seed / Jan 16, 2024 | ||
| The company intended to focus on developing novel immune engagers. | $25M / Series A / Jun 07, 2023 | ||
Quanta Therapeutics
|
Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes. The company was founded in 2018 and is based in San Francisco, CA. | $50.7M / Series D / May 22, 2023 | |
| AmbAgon Therapeutics is a developer of cancer molecule therapeutics. The company offers research of a small molecule that augments a tumor-suppressing protein. AmbAgon Therapeutics was founded by Christian Ottmann, Lucas Brunsveld, and Michelle Arkin. | $85M / Series A / Jan 06, 2022 | ||
| Nitrase Therapeutics is a platform company developing drugs against a newly identified class of enzymes called Nitrases, initially targeting Parkinson’s disease. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases such as Parkinson’s. While the initial focus is onParkinson's disease, the company aims to expand its proprietary platform to include other disease indications. | $7M / Series A / Nov 02, 2021 | ||
|
Quanta Therapeutics
|
Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes. The company was founded in 2018 and is based in San Francisco, CA. | $60M / Series C / Oct 26, 2021 | |
| Jnana Therapeutics is a biotechnology company focused on discovering and developing medicines that improve patient lives. Utilizing its RAPID platform, the firm accelerates the identification of therapeutic targets and the creation of small molecule therapies for various diseases. Jnana aims to enhance drug discovery efficiency through advancedchemoproteomics techniques, addressing unmet medical needs. | $50M / Series B / Aug 18, 2021 | ||
| Starday Foods is a healthy and sustainable food products company. | $4M / Seed / Aug 17, 2021 | ||
| Stemson Therapeutics is driven by a vision where anyone battling the emotional trauma or social stigma of hair loss has an opportunity to truly cure their condition and safely restore their natural hair. Our engineered cells are combined with a unique tissue engineering solution and are capable of generating a net new supply of hair follicles forpatients in need. Stemson | $15M / Series A / Jul 15, 2021 | ||
| Ribon Therapeutics is a biotechnology company pioneering the discovery of new cancer medicines that target monoPARP proteins, critical regulators of cancer survival mechanisms.The diverse and central functions that PARPs, or poly(ADP-ribose) polymerases, play in cancer cell survival pathways are just emerging, and many of the seminal discoveriesin the field have been made by Ribon’s scientific founders. By combining insights from our founders and an experienced management team, Ribon is building a proprietary drug discovery platform to investigate the molecular action and biological function of a subset of the PARP protein family, called monoPARPs. Based on its platform, Ribon is creating a pipeline of innovative medicines that selectively target monoPARPs to treat cancer and may have the potential to impact other diseases. The company is backed by prominent life science investors, including The Column Group, U.S. Venture Partners, Deerfield Management and Osage University Partners. | $65M / Series C / Jun 14, 2021 | ||
| See all 49 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does AbbVie Biotech Ventures invest in?
AbbVie Biotech Ventures invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 49 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is AbbVie Biotech Ventures's check size?
AbbVie Biotech Ventures typically joins rounds of $6M–$53M at Series A, $12M–$83M at Series B and $39M–$115M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds AbbVie Biotech Ventures participates in.
How do I contact AbbVie Biotech Ventures?
Public channels for AbbVie Biotech Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at AbbVie Biotech Ventures?
The team at AbbVie Biotech Ventures includes Jay Cui (Manager), John Gustofson (Managing Director) and Scott Brun (Head). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
